IMMUTEP LIMITED (IMM)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

IMM

IMM - IMMUTEP LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -0.02
Index: ASX300 | ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.24

11 Sep
2025

0.005

OPEN

$0.24

2.13%

HIGH

$0.24

1,234,740

LOW

$0.23

TARGET
$0.46 91.7% upside
OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGH . AGN . ARX . AVH . BIO . BOT . CSL . CUV . DXB . GSS . HXL . IDT . IMU . IVX . LGP . MAP . MSB . MVP . MYX . NEU . NUZ . NXS . OCC . OPT . OSL . PAR . PER . PNV . PYC . RAC . RCE . SNT . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS
IMM: 1
Title FY24
Actual		 FY25
Actual		 FY26
Forecast		 FY27
Forecast
EPS (cps) xxx - 4.2 - 5.9 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 202020212022202320242025
EPS Basic xxxxxxxxxxxxxxx-4.2
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx0.0 M
Book Value Per Share xxxxxxxxxxxxxxx9.8
Net Operating Cash Flow xxxxxxxxxxxxxxx-62.0 M
Net Profit Margin xxxxxxxxxxxxxxx-

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202020212022202320242025
Return on Capital Employed xxxxxxxxxxxxxxx-36.88 %
Return on Invested Capital xxxxxxxxxxxxxxx-36.70 %
Return on Assets xxxxxxxxxxxxxxx-34.27 %
Return on Equity xxxxxxxxxxxxxxx-36.88 %
Return on Total Capital xxxxxxxxxxxxxxx-41.65 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-62.1 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202020212022202320242025
Short-Term Debt xxxxxxxxxxxxxxx1 M
Long Term Debt xxxxxxxxxxxxxxx0 M
Total Debt xxxxxxxxxxxxxxx2 M
Goodwill - Gross xxxxxxxxxxxxxxx0 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx130 M
Price To Book Value xxxxxxxxxxxxxxx2.44

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202020212022202320242025
Capex xxxxxxxxxxxxxxx0.3 M
Capex % of Sales xxxxxxxxxxxxxxx-
Cost of Goods Sold xxxxxxxxxxxxxxx2 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx68 M
Research & Development xxxxxxxxxxxxxxx50 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

04/09/2025

1

Speculative Buy

$0.46

91.67%

Bell Potter highlights Immutep is actively seeking a global Phase 3 clinical trial in patients with non-small cell lung cancer (NSCLC), with final results expected to be two years down the track.

Interim results and updates will be available, including an initial futility analysis based on ORR data which is due out in 1Q 2026, with an interim PFS analysis in 2027.

Cash on hand stands at $130m as at June 30, which should last until the end of 2026 at around $22m per quarter.

Bell Potter maintains a Speculative Buy rating and cuts the target price to 46c from 70c.

FORECAST
Bell Potter forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -5.90 cents.
Bell Potter forecasts a full year FY27 dividend of 0.00 cents and EPS of minus -5.50 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

2

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Canaccord Genuity

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Wilsons

21/07/2025

1

Overweight

$1.20

400.00%

Wilsons notes recent updates from Immutep's Insight-003 and Tacti-003 trials reinforce the potential of Efti in cancer treatment.

In the background, the company has also been working on IMP761, a first-in-class LAG-3 that works by suppressing immune activity rather than stimulating T cells.

The broker believes IMP761 has the potential to treat autoimmune diseases such as rheumatoid arthritis and inflammatory bowel disease.

A phase 1 trial in healthy volunteers is underway, and the broker has incorporated the antibody's potential into its forecasts.

Overweight. Target rises to $1.20 from $1.05.

FORECAST
Wilsons forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -5.70 cents.
Access Extra Coverage Research History >

IMM STOCK CHART

FNArena News on IMM

1
Rudi’s View: Catalyst Metals, Dexus, Neuren, Stockland, ResMed & More

Sep 04 2025 - Rudi's View
2
Australian Broker Call *Extra* Edition – Aug 07, 2025

Aug 07 2025 - Daily Market Reports
3
Australian Broker Call *Extra* Edition – Jul 21, 2025

Jul 21 2025 - Daily Market Reports
4
Australian Broker Call *Extra* Edition – May 19, 2025

May 19 2025 - Daily Market Reports
5
Australian Broker Call *Extra* Edition – May 08, 2025

May 08 2025 - Daily Market Reports

Latest Pharmaceuticals & Biotech/Lifesciences News

1
Earnings Result Leaves CSL Bloodied

Aug 21 2025 - Australia
2
Renewed Momentum For CSL Shares

Jul 22 2025 - Technicals
3
Treasure Chest: CSL Not A One-Trick Pony

Jul 14 2025 - Treasure Chest
4
The Enigma Surrounding Clinuvel

Jul 03 2025 - Small Caps
5
Rudi’s View: CSL & NextDC

May 08 2025 - Rudi's View
6
Behring Margin Outlook Still Main Game For CSL

Feb 13 2025 - Australia
7
Dr Boreham’s Crucible: Arovella Therapeutics

Aug 29 2024 - Small Caps
8
ResMed’s Margin Upside Excites

Aug 07 2024 - Australia
9
Dr Boreham’s Crucible: Aroa Biosurgery

Jul 29 2024 - Small Caps
10
CSL Shares Breaking Free

Jul 23 2024 - Technicals